ClinicalTrials.gg
RecruitingNCT04005508POACHUpdated Jun 12, 2024

OSA and CV Outcomes in Patients With High Risk AF

An observational study in Atrial Fibrillation and Obstructive Sleep Apnea, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 22 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by National University of Singapore · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,365
Ages
22 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Atrial Fibrillation with a site in Singapore — 5 open to participants now, 9 under way, 1 of them phase 3. Atrial Fibrillation · Singapore.

Planned enrollment
9th of 14
1,365 · median 2,062
Started
2019
with 1 other
Observational
14 of 38
2 open now
Registered
28th of 38
by date

Among the 38 studies in Atrial Fibrillation with a site in Singapore, this one is the 9th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2019, is one of 14 observational ones, and was the 28th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

5 of the 38 studies in Atrial Fibrillation with a site in Singapore are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Atrial Fibrillation with a site in Singapore, or all of them as a file.
02

Study summary

The POACH study is part of the Cardiosleep research program. It is a prospective, observational, multicentre study conducted in Singapore. The recruitment target is 1365 patients.

Eligible patients with AF and high cardiovascular risk will be recruited for a home-based sleep study using a FDA-approved portable device. The patients will be divided into 2 groups based on the presence or absence of OSA using apnoea-hypopnoea index ≥ 15 events/hour. The AF will be treated as per local standard practice. Participation in the POACH study will not affect the management of AF. Follow-up will be conducted every 6 months until the median follow-up duration has reached 2 years. The primary endpoint is a four-component composite of all-cause mortality, myocardial infarction, stroke and heart failure hospitalisation.

Antecubital venous blood samples will be taken from the patients in the morning after the sleep study for targeted mass spectrometry which will measure 83 circulating metabolites. Sparse Principal Component Analysis will be used for data reduction. Identification of distinct associations between metabolic perturbations and OSA will be performed.

Read the detailed description

The overarching objective of the POACH study is to determine the impact of obstructive sleep apnoea (OSA) on cardiovascular outcomes in patients with atrial fibrillation (AF).

AF is the most prevalent sustained arrhythmia. While OSA often co-exists with AF, current management of AF does not take OSA status into consideration. This is partly due to the lack of data on whether OSA is independently associated with cardiovascular events in patients with AF. Besides, metabolomics is an emerging field of 'omics' research focusing on profiling and quantifying low-molecular weight components.

The POACH study is part of the Cardiosleep research program. It is a prospective, observational, multicentre study conducted in Singapore. The recruitment target is 1365 patients.

Eligible patients with AF and high cardiovascular risk will be recruited for a home-based sleep study using a FDA-approved portable device. The patients will be divided into 2 groups based on the presence or absence of OSA using apnoea-hypopnoea index ≥ 15 events/hour. The AF will be treated as per local standard practice. Follow-up will be conducted every 6 months until the median follow-up duration has reached 2 years. The primary endpoint is a four-component composite of all-cause mortality, myocardial infarction, stroke and heart failure hospitalisation. Antecubital venous blood samples will be taken from the patients in the morning after the sleep study for targeted mass spectrometry which will measure 83 circulating metabolites. Sparse Principal Component Analysis will be used for data reduction. Identification of distinct associations between metabolic perturbations and OSA will be performed.

Results of the POACH study will likely impact the care of patients with AF.

03

Conditions studied

  • Atrial Fibrillation
  • Obstructive Sleep Apnea

Keywords

  • sleep
  • cardiovascular outcomes
  • high cardiovascular risk
  • observational
04

Who can participate

Ages eligible
22 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with AF and high cardiovascular risk

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 22 or above
  2. Known AF, including paroxysmal, persistent or permanent AF
  3. High cardiovascular risk, defined as one or more of the following:

    • hypertension
    • diabetes mellitus
    • stroke
    • significant coronary artery disease (at least one stenosis of >50% diameter in at least one major epicardial artery based on CT or conventional coronary angiography, positive stress test [treadmill, myocardial perfusion scan, or stress echocardiography], previous percutaneous coronary intervention, or previous coronary artery bypass surgery)
    • chronic kidney disease (excluding polycystic kidney disease) with an estimated of \<60 ml/min/1.73m2,
    • 10-year risk of cardiovascular disease of 15% or greater on the basis of the Framingham risk score, or
    • age of 75 years or older

Exclusion criteria

Exclusion Criteria:

  1. Known OSA on regular CPAP treatment
  2. Valvular AF (moderate/severe mitral stenosis or mechanical heart valve)
  3. Permanent pacemaker implantation
  4. less than 1 year based on concomitant medical conditions
  5. Unable to give research consent
  6. Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,365 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • OSA (Watch PAT AHI >/= 15 events per hour)

    Patients found to have OSA by an overnight sleep study

    Diagnostic Test: Overnight sleep study

  • Non-OSA (Watch PAT AHI < 15 events per hour)

    Patients found NOT to have OSA by an overnight sleep study

    Diagnostic Test: Overnight sleep study

Interventions

  • Diagnostic testOvernight sleep study

    The patients will undergo an overnight sleep study using Watch-PAT sleep study device

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events

    Composite of all-cause mortality, myocardial infarction, stroke and heart failure hospitalization

    Time frame: 5 years

Secondary outcomes

  1. All-cause mortality

    Death due to any cause

    Time frame: 5 years

  2. All-cause mortality, myocardial infarction, or stroke

    tripe composite endpoint

    Time frame: 5 years

  3. Cardiovascular death

    Death due to cardiovascular cause

    Time frame: 5 years

  4. Cardiovascular death, myocardial infarction, or stroke

    tripe composite endpoint

    Time frame: 5 years

  5. Ischemic stroke

    Stroke is defined as global or focal cerebral, spinal cord or retinal injury resulting in acute neurological dysfunction due to ischemia

    Time frame: 5 years

  6. Heart failure hospitalisation

    the presence of congestive heart failure being the primary disease process accounting for clinical and physical signs of heart failure, with a need for additional or increased heart failure therapy, requiring at least a 24 hour stay in an inpatient unit or emergency department

    Time frame: 5 years

  7. Recurrence of AF after attempts at rhythm control

    Recurrence of AF after attempts at rhythm control (pharmacological, catheter, or cardioversion)

    Time frame: 5 years

  8. AF Progression

    Defined as (1) paroxysmal AF at baseline becoming persistent or permanent at the last follow-up visit or (2) persistent AF at baseline becoming permanent at the last follow-up visit.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Chi-Hang Lee
    Singapore, 119228, Singapore
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Jun 2025, 71 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 71 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2019
First posted
Jul 2, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2028
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04005508
Collaborators
Ng Teng Fong General Hospital, National University Hospital, Singapore, Singapore General Hospital
Responsible party
Chi-Hang Lee (Professor, National University of Singapore) — Principal investigator
First posted
Jul 2, 2019
Start date
Jul 1, 2019
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 12, 2024

Study contacts

Shalini Lobo, BSc
Contact
shalilb@nus.edu.sg
67795555 ext. 2493
Junping Liu, BSc
Contact
junping_liu@nuhs.edu.sg
67795555 ext. 2493
Chi-Hang R Lee, MD
principal investigator · National University of Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion